Trial Profile
A Dose Escalation, Safety, Pharmacokinetic, Pharmacodynamic and Preliminary Efficacy Study of SAR650984 (Isatuximab) Administered Intravenously in Combination With Bortezomib - Based Regimens in Adult Patients With Newly Diagnosed Multiple Myeloma Non Eligible for Transplantation
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Isatuximab (Primary) ; Bortezomib; Cyclophosphamide; Dexamethasone; Dexamethasone; Lenalidomide
- Indications Multiple myeloma; Smoldering multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CyBorDSAR
- Sponsors Sanofi
- 26 Jan 2024 Status changed from active, no longer recruiting to completed.
- 12 Dec 2023 Results (n=15) assessing Blood-Based Mass Spectrometry MRD Tracking (M-InSight) in Multiple Myeloma Patients presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 20 Oct 2023 Planned End Date changed from 23 Aug 2023 to 9 Feb 2024.